Loading
 

 

Oregon Bulletin

July 1, 2012

Oregon Board of Naturopathic Medicine, Chapter 850

Rule Caption: Amendments existing licensing requirements and making examination and license application requirements separate rules.

Adm. Order No.: OBNM 2-2012

Filed with Sec. of State: 6-15-2012

Certified to be Effective: 6-15-12

Notice Publication Date: 5-1-2012

Rules Adopted: 850-030-0031

Rules Amended: 850-030-0010, 850-030-0030, 850-030-0070

Rules Repealed: 850-030-0010(T), 850-030-0030(T), 850-030-0031(T), 850-030-0070(T)

Subject: 850-030-0010, 850-030-0030, and 850-030-0070 are being amended to clarify existing licensing requirements by application and examination.

 850-030-0031 is a new rule to split the existing examination and license application requirements into two separate clarifying rules. Requirements are currently found in one rule – 850-030-0030.

Rules Coordinator: Anne Walsh—(971) 673-0193

850-030-0010

Requirements for Application

(1) An individual applying for a license to practice in Oregon must undergo examination as provided in OAR 850-030-0030 and comply with OAR 850-030-0031 before the Board may issue a license to practice Naturopathic medicine in Oregon.

(2) An applicant for examination may submit information required for a criminal background check with application for examination. This information is required with the application for licensure, and a criminal background check must be completed before a license can be issued.

(3) An individual seeking to take the Naturopathic Physician Licensing Examinations (NPLEX) must register through the North American Board of Naturopathic Examiners (NABNE) and meet the qualifications established by NABNE. The Board does not administer NPLEX examinations.

(4) An individual who seeks to obtain a license by reciprocity must comply with OAR 850-030-0070.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.070 & 685.080
Hist.: NE 2, f. 6-7-59; NE 2-1984, f. & ef. 2-28-84; NE 1-1986, f. & ef. 4-10-86; NE 3-1990(Temp), f. 11-27-90, cert. ef. 12-1-90; Renumbered from 850-010-0010, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 1-2012(Temp), f. & cert. ef. 4-12-12 thru 10-4-12; OBMN 2-2012, f. & cert. ef. 6-15-12

850-030-0030

Application for Examination

(1) An individual applying for a license by examination must pass the following Naturopathic Physician Licensing Examinations (NPLEX) that are administered by the North American Board of Naturopathic Examiner (NABNE): the basic science examination also known as the NPLEX Part I Biomedical Science examination, the core clinical examinations also known as NPLEX Part II Clinical Science examinations and the clinical elective Minor Surgery examination.

(2) An individual applying for a license must pass the following state examinations: the Formulary and Jurisprudence examinations. To be eligible to sit for the state Formulary or Jurisprudence examinations an applicant must have passed NPLEX Part I, and be eligible to sit for NPLEX Part II and Minor Surgery examination, or have already passed Part I, Part II and the Minor Surgery examinations.

(3) An applicant applying to take the state Formulary or Jurisprudence examinations for Oregon must:

(a) Submit a completed application, furnished by the Board. If the applicant is applying to take both examinations, the applicant may submit one application for both exams;

(b) Submit a copy of the applicant’s diploma of graduation from the school of naturopathic medicine accredited by the Council of Naturopathic Medical Education (CNME);

(c) Have transcripts from any school of naturopathic medicine attended by the applicant submitted to the Board directly from the school; and

(d) Pay the non-refundable fees per 850-030-0035.

(4) An applicant may submit fingerprint cards and the fee for the criminal background check at the same time as submitting the application for examination. Fingerprint cards for the criminal background check are not required to take the Formulary or Jurisprudence examinations, but failure to submit the cards with the examination application may increase the time before a license may be issued when the applicant submits the application for licensure.

(5) An applicant may have undergraduate transcripts submitted directly from the college or university to the Board from the colleges or universities the individual attended and which attendance was used to support admission into the naturopathic school from which the individual graduated, at the same time as submitting the application for examination. Undergraduate transcripts are not required to take the state examinations, but failure to submit the transcripts prior to application for licensure, may increase the time before a license may be issued when the applicant submits the application for licensure.

(6) The Board may allow a licensee or other individual who is not applying for licensure by examination to apply for and take the state Formulary or Jurisprudence examination on a case-by-case basis.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.070
Hist.: NE 2, f. 6-7-59; NE 2-1984, f. & ef. 2-28-84; BNE 6-2001, f. 10-9-01, cert. ef. 1-1-02; Renumbered from 850-010-0030, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 1-2012(Temp), f. & cert. ef. 4-12-12 thru 10-4-12; OBMN 2-2012, f. & cert. ef. 6-15-12

850-030-0031

Application for License

(1) An individual must submit the following for a license application:

(a) A completed license application, on the form furnished by the Board;

(b) Arrange for NABNE to submit to the Board proof that the individual has successfully passed the required NPLEX examinations;

(c) Successfully pass the Oregon Formulary and Jurisprudence examinations;

(d) Have undergraduate transcripts submitted directly from the college or university to the Board from the colleges or universities the individual attended and which attendance was used to support admission into the naturopathic school from which the individual graduated;

(e) Submit to a national criminal background check per ORS 685.195 by providing to the Board fingerprint cards that can be read for purposes of a background check along with the required fee under OAR 850-030-0035;

(f) Pay the non-refundable license application fee under OAR 850-030-0035.

(2) To qualify for a license an individual must submit the completed application for licensure within one year of receiving notification of successfully passing all the required examinations. If the individual does not submit the complete application within one year of passing the required examinations, the Board may no longer accept the results on all the examinations, in which case one or more of the examinations may need to be retaken.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.080
Hist.: OBNM 1-2012(Temp), f. & cert. ef. 4-12-12 thru 10-4-12; OBMN 2-2012, f. & cert. ef. 6-15-12

850-030-0070

License by Reciprocity

The Board on an individual basis may consider reciprocity for individuals who hold an active license to practice naturopathic medicine in good-standing in another state, jurisdiction or territory of the United States, the District of Columbia or Canada.

(1) If an individual is currently licensed as a naturopathic physician in good-standing in another licensing state or jurisdiction following successful completion of the NPLEX examinations required by Oregon, the individual must submit a complete license application within two years after successfully passing the required state examinations administered by the Board.

(a) The individual must have verification that he or she is licensed and in good-standing as a naturopathic physician directly submitted from the state(s) or jurisdiction(s) in which license is held.

(b) If the individual does not submit a complete license application within two years of passing the required state examinations, the Board may no longer accept the individual’s results on all of the required examinations in which case one or more of all the exams may need to be retaken.

(2) To qualify for license by reciprocity an individual must submit the following for a license:

(a) A completed license application, on the form furnished by the Board;

(b) Arrange for NABNE to submit to the Board proof that the individual has successfully passed the NPLEX examinations required by the Board;

(c) Successfully pass the Oregon Formulary and Jurisprudence examinations;

(d) Have undergraduate transcripts submitted directly from the college or university to the Board from the colleges or universities the individual attended and which attendance was used to support admission into the naturopathic school from which the individual graduated;

(e) Submit to a national criminal background check per ORS 685.195 by providing to the Board fingerprint cards that can be read for purposes of a background check along with the required fee under OAR 850-030-0035;

(f) Pay the non-refundable license application fee under OAR 850-030-0035.

(3) An applicant may submit fingerprint cards and the fee for the criminal background check at the same time as submitting the application for the Formulary or Jurisprudence examinations. Fingerprint cards are not required to take the Formulary or Jurisprudence examinations, but may delay licensure once an application for license in made.

(4) Applicants for license by reciprocity must possess qualifications equal to those required of persons eligible for licensure by examination. An application for license by reciprocity will be denied if applicant does not meet all those qualifications.

Stat. Auth.: ORS 68.125
Stats. Implemented: ORS 685.085
Hist.: NE 2, f. 6-7-59; NE 2-1984, f. & ef. 2-28-84; BNE 7-2001, f. 10-9-01, cert. ef. 1-1-02; Renumbered from 850-010-0070, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 1-2012(Temp), f. & cert. ef. 4-12-12 thru 10-4-12; OBMN 2-2012, f. & cert. ef. 6-15-12


 

Rule Caption: Amends Formulary to include Nitrous Oxide; Brings 850-050-0120 compliant with ORS 676.150.

Adm. Order No.: OBNM 3-2012

Filed with Sec. of State: 6-15-2012

Certified to be Effective: 6-15-12

Notice Publication Date: 5-1-2012

Rules Amended: 850-050-0120, 850-060-0226

Subject: 850-060-0225 corrects a numbering error and adds nitrous oxide to 850-060-0226(8)(f)(B)(i).

 850-050-0120 amends the language to be consistent with statute ORS 676.150.

Rules Coordinator: Anne Walsh—(971) 673-0193

850-050-0120

Illegal Practice; Duty to Self-Report

(1) No person, including a graduate of any naturopathic medicine program, other than a licensee complying with the provisions of ORS Chapter 685 shall:

(a) Practice naturopathic medicine or naturopathy in Oregon, or

(b) Advertise, hold out to the public or represent in any manner that the person is authorized to practice naturopathy or naturopathic medicine in Oregon, or

(c) Use the terms “naturopathic practitioner,” “naturopathic healer,” “naturopathic doctor,” “naturopathic consultant” or any other terms that convey intent to practice naturopathy or naturopathic medicine.

(2) Any person convicted of practicing illegally in Oregon or any person who, without a license, makes a diagnosis shall not be admitted to examination by the Board at any time.

(3) It shall be the duty of all Board licensees, in the interests of both the public and the profession, to inform the Board, in writing, of anyone practicing naturopathy or naturopathic medicine in Oregon without a license or otherwise in violations of the law.

(4) For the purpose of this rule, naturopathic treatment shall be considered as practicing naturopathy or naturopathic medicine within the meaning of ORS 685.010(5), unless under the direct supervision of a licensee of the Board.

(5) Each Board licensee must self-report to the Board in writing as soon as possible, but no later than 10 business days after official action taken against the licensee, of any of the following:

(a) Any conviction of the licensee for a misdemeanor crime;

(b) Any arrest or conviction of the licensee for a felony crime;

(c) Any action brought against the licensee by a health regulatory agency; and

(d) Any action brought against the licensee by a patient, former patient, or health care facility, based upon allegations or findings of medical incompetence, malpractice, unprofessional conduct or licensee impairment.

Stat. Auth.: ORS 685
Stats. Implemented: ORS 685.220, 685.110 & 676.150
Hist.: NE 2, f. 6-7-59; BNE 4-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0120, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 5-2008, f. & cert. ef. 6-11-08; OBNM 4-2010, f. & cert. ef. 6-30-10; OBNM 6-2011, f. 12-15-11, cert. ef. 12-23-11; OBNM 3-2012, f. & cert. ef. 6-15-12

850-060-0226

Formulary Compendium Classifications

The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

(1) Antihistamine Drugs;

(a) First Generation Antihistamine Drugs;

(A) Ethanolamine Derivatives;

(B) Ethylenediamine Derivatives;

(C) Phenothiazine Derivatives;

(D) Piperazine Derivatives;

(E) Propylamine Derivatives;

(F) Miscellaneous Derivatives;

(b) Second Generation Antihistamines.

(2) Anti-Infective Agents;

(a) Antihelmintics;

(b) Antibacterials;

(A) Aminoglycosides;

(B) Cephalosporins;

(i) First Generation Cephalosporins;

(ii) Second Generation Cephalosporins;

(iii) Third Generation Cephalosporins;

(iv) Fourth Generation Cephalosporins.

(C) Miscellaneous ß-Lactams;

(i) Carbacephems;

(ii) Carbapenems;

(iii) Cephamycins;

(iv) Monobactams.

(D) Chloramphenicol;

(E) Macrolides.

(i) Erythromycins;

(ii) Ketolides;

(iii) Other Macrolides.

(F) Penicillins;

(i) Natural Penicillins;

(ii) Aminopenicillins;

(iii) Penicillinase-resistant Penicillins;

(iv) Extended-spectrum Penicillins.

(G) Quinolones;

(H) Sulfonamides;

(I) Tetracyclines: Glycylcyclines;

(J) Antibacterials, Miscellaneous.

(i) Aminocyclitols;

(ii) Bacitracins;

(iii) Cyclic Lipopeptides;

(iv) Glycopeptides;

(v) Lincomycins;

(vi) Oxazolidinones;

(vii) Polymyxins;

(viii) Rifamycins;

(ix) Streptogramins;

(c) Antifungals;

(A) Allylamines;

(B) Azoles;

(C) Echinocandins;

(D) Polyenes;

(E) Pyrimidines;

(F) Antifungals, Miscellaneous.

(d) Antimycobacterials;

(A) Antituberculosis Agents;

(B) Antimycobacterials, Miscellaneous.

(e) Antivirals;

(A) Adamantanes;

(B) Antiretrovirals;

(i) HIV Fusion Inhibitors;

(ii) HIV Protease Inhibitors;

(iii) Integrase Inhibitors;

(iv) Nonnucleoside Reverse Transcriptase Inhibitors;

(v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors

(C) Interferons;

(D) Monoclonal Antibodies;

(E) Neuraminidase Inhibitors;

(F) Nucleosides and Nucleotides;

(G) Antivirals, Miscellaneous;

(f) Antiprotozoals;

(A) Amebicides;

(B) Antimalarials;

(C) Antiprotozoals, Miscellaneous.

(3) Antineoplastic Agents (oral and topical only) limited to the following:

(a) 5FU;

(b) Anastrozole;

(c) Letrozole;

(d) Megestrol;

(e) Mercaptopunne;

(f) Methotrexate;

(g) Tamoxifen;

(h) Tretinoin.

(4) Autonomic Drugs;

(a) Parasympathomimetic (Cholinergic) Agents;

(b) Anticholinergic Agents: Antimuscarinics/ Antispasmodics;

(c) Sympathomimetic (Adrenergic) Agents;

(A) a-Adrenergic Agonists;

(B) ß- Adrenergic Agonists;

(i) Non-selective ß- Adrenergic Agonists;

(ii) Selective ß1- Adrenergic Agonists;

(iii) Selective ß2- Adrenergic Agonists;

(C) a-And ß-Adrenergic Agonists;

(d) Sympatholytic (Adrenergic Blocking) Agents;

(e) Skeletal Muscle Relaxants;

(A) Centrally Acting Skeletal Muscle Relaxants;

(B) Direct-acting Skeletal Muscle Relaxants;

(C) GABA-derivative Skeletal Muscle Relaxants;

(D) Neuromuscular Blocking Agents;

(E) Skeletal Muscle Relaxants, Miscellaneous.

(f) Autonomic Drugs, Miscellaneous.

(5) Blood Derivatives.

(6) Blood Formation, Coagulation, and Thrombosis;

(a) Antianemia Drugs: Iron Preparations;

(b) Antithrombotic Agents;

(A) Anticoagulants;

(i) Coumarin Derivatives;

(ii) Direct Thrombin Inhibitors;

(iii) Heparins;

(iv) Anticoagulants, Miscellaneous.

(B) Platelet-reducing Agents;

(C) Platelet-aggregation Inhibitors;

(D) Thrombolytic Agents;

(c)Hematopoietic Agents;

(d) Hemorrheologic Agents;

(e) Antihemorrhagic Agents;

(A) Antiheparin Agents;

(B) Hemostatics.

(7) Cardiovascular Drugs;

(a) Cardiac Drugs;

(A) Antiarrhythmic Agents;

(i) Class Ia Antiarrhythmics;

(ii) Class Ib Antiarrhythmics;

(iii) Class Ic Antiarrhythmics;

(iv) Class III Antiarrhythmics;

(v) Class IV Antiarrhythmics.

(B) Cardiotonic Agents;

(C) Cardiac Drugs, Miscellaneous.

(b) Antilipemic Agents;

(A) Bile Acid Sequestrants;

(B) Cholesterol Absorption Inhibitors;

(C) Fibric Acid Derivatives;

(D) HMG-CoA Reductase Inhibitors;

(E) Antilipemic Agents, Miscellaneous.

(c) Hypotensive Agents;

(A) Calcium-Channel Blocking Agents;

(B) Central a-Agonists;

(C) Direct Vasodilators;

(D) Peripheral Adrenergic Inhibitors.

(d) Vasodilating Agents;

(A) Nitrates and Nitrites;

(B) Phosphodiesterase Inhibitors;

(C) Vasodilating Agents, Miscellaneous.

(e) Sclerosing Agents;

(f) a-Adrenergic Blocking Agents;

(g) ß-Adrenergic Blocking Agents;

(h) Calcium-Channel Blocking Agents;

(A) Dihydropyridines;

(B) Calcium-Channel Blocking Agents, Miscellaneous;

(i) Renin-Angiotensin-Aldosterone System Inhibitors;

(A) Angiotensin-Converting Enzyme Inhibitors;

(B) Angiotensin II Receptor Antagonists;

(C) Mineralocorticoid (Aldosterone) Receptor Antagonists;

(D) Renin Inhibitors.

(8) Central Nervous System Agents;

(a) Analgesics and Antipyretics;

(A) Nonsteroidal Anti-inflammatory Agents;

(i) Cyclooxygenase-2 (COX-2) Inhibitors;

(ii) Salicylates;

(iii) Other Nonsteroidal Anti-inflammatory Agents;

(B) Opiate Agonists;

(C) Opiate Partial Agonists;

(D) Analgesics and Antipyretics, Miscellaneous.

(b) Opiate Antagonists;

(c) Anticonvulsants, does not include Barbiturates;

(A) Benzodiazepines;

(B) Hydantoins;

(C) Succinimides;

(D) Anticonvulsants, Miscellaneous.

(d) Psychotherapeutic Agents;

(A) Antidepressants;

(i) Monoamine Oxidase Inhibitors;

(ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;

(iii) Selective Serotonin- Reuptake Inhibitors;

(iv) Serotonin Modulators;

(v) Tricyclics and Other Norepinephrine-reuptake Inhibitors.

(vi) Antidepressants, Miscellaneous.

(B) Antipsychotics, to include only the following: Atypical antipsychotics.

(e) Anorexigenic Agents and Respiratory and Cerebral Stimulants.

(A) Amphetamines.

(B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous.

(f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;

(A) Benzodiazepines;

(B)(i) Anxiolytics, Seditives, and Hypnotics; Miscellaneous;

(ii) Nitrous oxide;

(g) Antimanic Agents;

(h) Antimigraine Agents: Selective Serotonin Agonists;

(i) Antiparkinsonian Agents;

(A) Adamantanes;

(B) Anticholinergic Agents;

(C) Catechol-O-Methyltransferase (COMT) Inhibitors;

(D) Dopamine Precursors;

(E) Dopamine Receptor Agonists;

(i) Ergot-derivative Dopamine Receptor Agonists;

(ii) Non-ergot-derivative Dopamine Receptor Agonists;

(F) Monoamine Oxidase B Inhibitors;

(j) Central Nervous System Agents, Miscellaneous.

(9) Contraceptives (foams, devices).

(10) Diagnostic Agents.

(11) Disinfectants (for Agents used on objects other than skin).

(12) Electrolytic, Caloric, and Water Balance;

(a) Acidifying Agents;

(b) Alkalinizing Agents;

(c) Ammonia Detoxicants;

(d) Replacements Preparations;

(e) Ion-Removing Agents;

(A) Calcium-removing Agents;

(B) Potassium-removing Agents;

(C) Phosphate-removing Agents;

(D) Other Ion-removing Agents;

(f) Caloric Agents;

(g) Diuretics;

(A) Loop Diuretics;

(B) Osmotic Diuretics;

(C) Potassium-sparing Diuretics;

(D) Thiazide Diuretics;

(E) Thiazide-like Diuretics;

(F) Diuretics, Miscellaneous;

(h) Irrigation Solutions;

(i) Uricosuric Agents.

(13) Enzymes.

(14) Respiratory Tract Agents;

(a) Antihistamines;

(b) Antitussives;

(c) Anti-inflammatory Agents;

(A) Leukotriene Modifiers;

(B) Mast-cell Stabilizers;

(d) Expectorants;

(e) Pulmonary Surfactants;

(f) Respiratory Agents, Miscellaneous.

(15) Eye, Ear, Nose, and Throat (EENT) Preparations;

(a) Antiallergic Agents;

(b) Anti-infectives;

(A) Antibacterials;

(B) Antifungals;

(C) Antivirals;

(D) Anti-infectives, Miscellaneous.

(c) Anti-inflammatory Agents;

(A) Corticosteroids;

(B) Nonsteroidal Anti-inflammatory Agents;

(C) Anti-inflammatory Agents, Miscellaneous.

(d) Local Anesthetics;

(e) Mydriatics;

(f) Mouthwashes and Gargles;

(g) Vasoconstrictors;

(h) Antiglaucoma Agents;

(A) a-Adrenergic Agonists;

(B) ß-Adrenergic Agents;

(C) Carbonic Anhydrase Inhibitors;

(D) Miotics;

(E) Prostaglandin Analogs;

(i) EENT Drugs, Miscellaneous.

(16) Gastrointestinal Drugs;

(a) Antacids and Adsorbents;

(b) Antidiarrhea Agents;

(c) Antiflatulents;

(d) Cathartics and Laxatives;

(e) Cholelitholytic Agents;

(f) Emetics;

(g) Antiemetics;

(A) Antihistamines;

(B) 5-HT3 Receptor Antagonists;

(C) Antiemetics, Miscellaneous.

(h) Antiulcer Agents and Acid Suppressants;

(A) Histamine H2-Antogonists;

(B) Prostaglandins;

(C) Protectants;

(D) Proton-pump Inhibitors;

(i) Prokinetic Agents;

(j) Anti-inflammatory Agents;

(k) GI Drugs, Miscellaneous.

(17) Gold Compounds.

(18) Heavy Metal Antagonists.

NOTE: IV administration requires education and training compliance with 850-060-0212.

(19) Hormones and Synthetic Substitutes;

(a) Adrenals;

(b) Androgens;

(c) Contraceptives;

(d) Estrogens and Antiestrogens;

(A) Estrogens;

(B) Estrogen Agonists-Antiagonists.

(e) Gonadotropins;

(f) Antidiabetic Agents;

(A) a-Glucosidase Inhibitors;

(B) Amylinomimetics;

(C) Biguanides;

(D) Dipeptidyl Peptidase (DDP-4) Inhibitors;

(E) Incretin Mimetics;

(F) Insulins;

(G) Meglitinides;

(H) Sulfonylureas;

(I) Thiazolidinediones.

(g) Antihypoglycemic Agents: Glycogenolytic Agents;

(h) Parathyroid;

(i) Pituitary;

(j) Somatotropin Agonists and Antagonists;

(A) Somatotropin Agonists;

(B) Somatotropin Antagonists;

(k) Progestins;

(l) Thyroid and Antithyroid Agents;

(A) Thyroid Agents;

(B) Antithyroid Agents.

(20) Local Anesthetics.

(21) Oxytocics, except for Mifepristone.

(22) Serums, Toxoids, and Vaccines;

(a) Serums;

(b) Toxoids;

(c) Vaccines.

(23) Skin and Mucous Membrane Agents;

(a) Anti-infectives;

(A) Antibacterials;

(B) Antivirals;

(C) Antifungals;

(i) Allylamines;

(ii) Azoles;

(iii) Benzylamines;

(iv) Hydroxypyridones;

(v) Polyenes;

(vi) Thiocarbamates;

(vii) Antifungals, Miscellaneous.

(D) Scabicides and Pediculicides;

(E) Local Anti-infectives, Miscellaneous.

(b) Anti-inflammatory Agents;

(c) Antipruritics and Local Anesthetics;

(d) Astringents;

(e) Cell Stimulants and Proliferants;

(f) Detergents;

(g) Emollients, Demulcents, and Protectants;

(h) Keratolytic Agents;

(i) Keratoplastic Agents;

(j) Depigmenting and Pigmenting Agents;

(A) Depigmenting Agents;

(B) Pigmenting Agents;

(k) Sunscreen Agents;

(l) Skin and Mucous Membrane Agents, Miscellaneous.

(24) Smooth Muscle Relaxants;

(a) Gastrointestinal Smooth Muscle Relaxants;

(b) Genitourinary Smooth Muscle Relaxants;

(c) Respiratory Smooth Muscle Relaxants.

(25) Vitamins.

(26) Miscellaneous Therapeutic Agents;

(a) Alcohol Deterrents limited to the following:

(A) Acamprosate;

(B) Disulfiram;

(C) Naltrexone.

(b) 5-a Reductase Inhibitors;

(c) Antidotes;

(d) Antigout Agents;

(e) Biologic Response Modifiers, limited to Interferons;

(f) Bone Resorption Inhibitors;

(g) Cariostatic Agents;

(h) Complement Inhibitors;

(i) Disease-Modifying Antirheumatic Agents;

(j) Gonadotropin-releasing Hormone Antagonists;

(k) Immunosuppressive Agents;

(l) Other Miscellaneous Therapeutic Agents limited to the following:

(A) Alfuzosin Hydrochloride;

(B) Drotrecogin Alfa (Activated);

(C) Lanreoytide Acetate;

(D) Rilonacept;

(E) Sapropterin Dihydrochloride;

(F) Tamsulosin Hydrochloride.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.145
Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11; OBNM 4-2011, f. & cert. ef. 6-15-11; OBNM 3-2012, f. & cert. ef. 6-15-12

 

Notes
1.) This online version of the OREGON BULLETIN is provided for convenience of reference and enhanced access. The official, record copy of this publication is contained in the original Administrative Orders and Rulemaking Notices filed with the Secretary of State, Archives Division. Discrepancies, if any, are satisfied in favor of the original versions. Use the OAR Revision Cumulative Index found in the Oregon Bulletin to access a numerical list of rulemaking actions after November 15, 2011.

2.) Copyright 2012 Oregon Secretary of State: Terms and Conditions of Use

Oregon Secretary of State • 136 State Capitol • Salem, OR 97310-0722
Phone: (503) 986-1523 • Fax: (503) 986-1616 • oregon.sos@state.or.us

© 2013 State of Oregon All Rights Reserved​